Why Atomo?
Consumers are embracing the power of at-home diagnostics and telehealth. We believe that fast, accurate point of care testing empowers people to enjoy healthier, more informed lives.
Our Story
After ten years as a senior leader in the medical device sector, Atomo’s Founder and CEO John Kelly identified multiple ways in which diagnostics were ripe for transformation. John observed that usability, convenience, and simplicity of use could make a real difference in diagnostics. When people can’t use a product the way it is intended, the performance is undermined.
While John was exploring areas of the market where usability was poorly delivered, his youngest daughter was born and required intensive medical care for the first two years of her life. He watched as doctors struggled to collect blood from her arm. When John found out that the blood test they were doing only required a tiny drop of blood, he had a light bulb moment. John decided to develop a better, less invasive way to collect a blood sample.
The Opportunity
This is a crucial time for healthcare. The growing consumer acceptance of telemedicine has revolutionised how healthcare is delivered, enabling patients to access medical care from the comfort of their homes. This shift has been driven by advancements in technology, increased internet accessibility, and a desire for more convenient and immediate healthcare solutions.
Patients and healthcare providers alike now expect real-time access to diagnostic information, which is critical for timely decision-making and effective treatment planning. This expectation has significantly increased the demand for rapid point-of-care diagnostics.
Point-of-care diagnostics offer the advantage of immediate results, which can be crucial in managing acute conditions, monitoring chronic diseases, and conducting routine health assessments. These diagnostics are particularly valuable in remote or underserved areas where access to traditional laboratory facilities is limited. The ability to conduct tests and obtain results quickly on-site enhances the overall efficiency of healthcare delivery and improves patient outcomes.
Vision & Mission
Values
Impact
Commercialising products that matter to our users
Innovation
Fostering creative thinking and solutions
Integrity
Ensuring honesty and fairness in all that we do
Collaboration
Working as one
global team
Excellence
Being recognised as experts in the field
Executive Team
John Kelly
Founder, Managing Director & CEO
For more than 20 years John Kelly has championed the cause of reimagining medical devices to enhance their usability and performance. Before founding Atomo Diagnostics in 2010, John was Chief Operating Officer at ASX listed (now NASDAQ listed) Unilife Corporation, where he led the ‘Unifill’ development team to develop the world’s first glass prefilled drug delivery device with integrated auto retract safety feature. This technology was successfully licensed to Sanofi Aventis. Previously, John led the New Product Implementation Group at ResMed, where he managed the design and commercialisation of the ground-breaking Mirage Swift mask. In addition to his commercial experience, John has an Honours Degree in Mechanical Engineering from the University of Liverpool, a Master’s Degree in Systems Engineering from Queen’s University Belfast, and an Executive MBA from the University of Sydney, where he was awarded the Business School’s inaugural ‘Excellence in Leadership’ scholarship.
Chandra Sukumar
Chief Operating Officer
Chandra joined Atomo in 2017 as Director of Programs bringing with her more than 25 years of experience within the medical device industry. She has extensive experience in the development of medical devices from conception to commercialisation. Prior to joining Atomo, she served in a variety of leadership roles within ResMed, including supply chain management, global manufacturing, and APAC marketing. Chandra holds a Bachelors Honours degree in Physics and an executive MBA from AGSM.
Board of Directors
John Keith
Non-Executive Chair
John is the Managing Director of BNP Paribas. Prior to that, he led management and coverage roles for Nomura Securities in Sydney and Hong Kong. John also serves as a Director of ASIA Limited, Calliva Limited, Room to Read Australia Foundation and Ascham Foundation.
Dr. Paul Kasian
Non-Executive Director
Chair of IODM Limited. Non-Executive Director of Eco Systems Ltd (ASX:ESL). Previously Chair and CEO of Genetic Technologies Limited. PhD in Microbiology and MBA, both from the University of Melbourne, and GAICD. Former Chief Investment Officer and Head of Global Financials at HSBC Asset Management; Founding Director of Accordius; Founding Director of Wallara Asset Management.
Deborah J. Neff
Non-Executive Director
A veteran of the life sciences industry building market-leading global businesses. As principal of DJN Consulting, LLC. based in the San Francisco Bay Area, Deborah currently works with several privately held healthcare startup companies providing strategic business advising and mentoring to the executive management teams. She was previously CEO of Evanostics, LLC., of Pathwork Diagnostics Inc., and COO at Complete Genomics Inc., following a 15-year career with Becton Dickinson Inc., where she last served as President of BD Biosciences (a major global business unit of the company). Deborah is currently a Director on the Board of Cytek Biosciences Inc, a NASDAq listed company, and also Chair of the Board of Guide Dogs for the Blind, Inc, a non-profit organization. Deborah also serves as the Chair of the Board of Trustees for the UCDavis Foundation. She previously served on the boards of Bio-Rad Inc, ForteBio, Inc (acquired by Pall Corp), and Advanced Medical Optics, Inc (acquired by Abbott).
Dr. Cheri Walker
Non-Executive Director
Dr. Walker is an executive with more than twenty-five years of experience working with life science and diagnostic companies. Employing years in the financial markets as a stock analyst, commercial execution to meet aggressive growth targets, and more than 45 successfully closed mergers, acquisitions and divestitures, she has worked as part of and with management teams, private equity and venture firms to develop the best strategies to build their life science business and to execute on acquisition strategies or sale of the company. Dr. Walker is currently the President, Chief Executive Officer, and Director of Rhinostics, an early-stage spin-out company based on technology initially developed at Harvard University. She has previously held senior executive positions at Abcam; Charles River Labs; Qiagen, and Life Technologies, now part of ThermoFisher. Dr. Walker holds a BA in Biology from Swarthmore College and a Ph.D. in Human and Molecular Genetics from Baylor College.
Work With Us
Atomo is a fast-growing dynamic company with tremendous opportunities for people interested in revolutionising healthcare through rapid point-of-care diagnostics.
We’re looking for energetic, creative, entrepreneurial people who have a keen interest in using technology to make the world a better place.
